Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Ebert

Showing results (161-170 of 339) with videos related to

Pageof 34
Sort By:
Blood|August 2, 2018
<i>Crbn</i> <sup>I391V</sup> is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in miceEmma C Fink, Marie McConkey, Dylan N Adams, et al.
Blood Advances|January 4, 2018
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cellsMia Eriksson, Pablo Peña-Martínez, Ramprasad Ramakrishnan, et al.
American Journal of Hematology|December 6, 2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.
Nature Chemical Biology|April 6, 2026
Charged molecular glue discovery enabled by targeted degron displayZhe Zhuang, Woong Sub Byun, Jakub Chrustowicz, et al.
Science (New York, N.Y.)|December 3, 2013
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsJan Krönke, Namrata D Udeshi, Anupama Narla, et al.
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Nature Medicine|October 19, 2021
Distinction of lymphoid and myeloid clonal hematopoiesisAbhishek Niroula, Aswin Sekar, Mark A Murakami, et al.
EMBO Molecular Medicine|February 14, 2024
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cellsJan Mueller, Roman R Schimmer, Christian Koch, et al.
JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
Blood|January 18, 2023
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data setsCaitlyn Vlasschaert, Taralynn Mack, J Brett Heimlich, et al.
Pageof 34

Showing results (161-170 of 339) with videos related to

Sort By:
Pageof 34
Blood|August 2, 2018
<i>Crbn</i> <sup>I391V</sup> is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in miceEmma C Fink, Marie McConkey, Dylan N Adams, et al.
Blood Advances|January 4, 2018
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cellsMia Eriksson, Pablo Peña-Martínez, Ramprasad Ramakrishnan, et al.
American Journal of Hematology|December 6, 2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.
Nature Chemical Biology|April 6, 2026
Charged molecular glue discovery enabled by targeted degron displayZhe Zhuang, Woong Sub Byun, Jakub Chrustowicz, et al.
Science (New York, N.Y.)|December 3, 2013
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsJan Krönke, Namrata D Udeshi, Anupama Narla, et al.
Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.
Nature Medicine|October 19, 2021
Distinction of lymphoid and myeloid clonal hematopoiesisAbhishek Niroula, Aswin Sekar, Mark A Murakami, et al.
EMBO Molecular Medicine|February 14, 2024
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cellsJan Mueller, Roman R Schimmer, Christian Koch, et al.
JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.
Blood|January 18, 2023
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data setsCaitlyn Vlasschaert, Taralynn Mack, J Brett Heimlich, et al.
Pageof 34